Company Description
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors.
In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform.
TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 154 |
| CEO | Dr. Gavin MacBeath Ph.D. |
Contact Details
Address: 880 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | 857-399-9500 |
| Website | tscan.com |
Stock Details
| Ticker Symbol | TCRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001783328 |
| CUSIP Number | 89854M101 |
| ISIN Number | US89854M1018 |
| Employer ID | 82-5282075 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gavin MacBeath Ph.D. | Chief Executive Officer and Director |
| Dr. Stephen J. Elledge Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Tomasz Kula Ph.D. | Co-Founder and Member of Advisory Board |
| Jason A. Amello | Chief Financial Officer |
| Leiden Dworak M.B.A. | Principal Accounting Officer and Treasurer |
| Dr. Justin McCue Ph.D. | Chief Technology Officer |
| Dr. Zoran Zdraveski J.D., Ph.D. | Chief Legal and Strategy Officer and Company Secretary |
| Ann Hargraves | Senior Vice President of Human Resources |
| Dr. Shrikanta Chattopadhyay M.D. | Senior Vice President and Head of Translational Medicine |
| Ray Lockard M.B.A. | Senior Vice President and Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 18, 2024 | 424B5 | Filing |
| Apr 17, 2024 | 8-K | Current Report |
| Apr 17, 2024 | FWP | Free Writing Prospectus |
| Apr 16, 2024 | 424B5 | Filing |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 12, 2024 | EFFECT | Notice of Effectiveness |
| Apr 10, 2024 | 10-K/A | [Amend] Annual report |
| Apr 8, 2024 | 8-K | Current Report |
| Mar 6, 2024 | S-3 | Registration statement under Securities Act of 1933 |